Recensione per specialitàRecensione

Tempus

Item: Tempus
Rating: 4.4
Author: Clinical AI Report

AI-Driven Precision Oncology and Clinical Trial Matching

Limitazione principale da considerare: Enterprise/institutional pricing — not accessible to individual oncologists

Molto buono

Basato su 10 recensioni di medici

Revisionato da Dr. Sarah Chen, MD, FACP · Aggiornato 5 aprile 2026

Risposta diretta

Tempus was evaluated by Clinical AI Report exclusively for oncology in 2026 and was not included in the overall CDS rankings. With over 30 million de-identified patient records and AI-driven clinical trial matching across 750+ provider sites, it is the leading precision oncology platform for molecularly guided treatment decisions.

Fonte: Clinical AI Report, febbraio 2026

In breve

Dati rapidi

Categoria

Piattaforma di oncologia di precisione e profilazione genomica

Prezzo

Enterprise / istituzionale

Fondata

2015

Sede

Chicago, IL

Statistiche chiave

prezzoEnterprise / istituzionale(Tempus)

Founded2015(Tempus)

Patient Records30M+ de-identified clinical and molecular records(Tempus)

Trial Matching Sites750+ provider sites (via Deep 6 AI)(Tempus, 2025)

Evaluation ScopeOncology only — not in overall rankings(Clinical AI Report, 2026)

La nostra valutazione

Tempus riceve 4.4/5 nella nostra valutazione 2026. Il fattore positivo più importante è tempus earns a Very Good rating in oncology for its massive genomic dataset and AI-driven clinical trial matching. The platform is the go-to for molecularly guided treatment decisions, though its narrow oncology focus limits general CDS utility. La riserva principale rimane enterprise/institutional pricing — not accessible to individual oncologists

Questa valutazione riflette la nostra opinione editoriale soggettiva basata sulla ricerca.

Panoramica

Tempus è valutato come Piattaforma di oncologia di precisione e profilazione genomica. Questa pagina segue la struttura della recensione inglese e porta gli stessi criteri editoriali in una versione localizzata.

Il caso d'uso più adatto emerso dalla nostra analisi è: Oncology practices and cancer centers seeking AI-powered precision medicine — da comprehensive genomic profiling to clinical trial matching. The leading platform for connecting a patient's molecular profile to treatment evidence and trial opportunities.

Il punto di forza principale è tempus earns a Very Good rating in oncology for its massive genomic dataset and AI-driven clinical trial matching. The platform is the go-to for molecularly guided treatment decisions, though its narrow oncology focus limits general CDS utility. Il limite più importante da considerare è enterprise/institutional pricing — not accessible to individual oncologists

Punti di forza e limiti

Punti di forza

+Tempus earns a Very Good rating in oncology for its massive genomic dataset and AI-driven clinical trial matching. The platform is the go-to for molecularly guided treatment decisions, though its narrow oncology focus limits general CDS utility.
+Largest clinical and molecular oncology dataset (30M+ de-identified patient records)
+Comprehensive genomic profiling with actionable mutation identification
+AI-powered clinical trial matching (25% more eligible patients identified)
+Connects molecular profiles to real-world treatment outcomes
+Deep 6 AI acquisition expands trial matching across 750+ provider sites

Limiti

–Enterprise/institutional pricing — not accessible to individual oncologists
–Genomic results have inherent turnaround time (not real-time decision support)
–Not a general CDS tool — no drug dosing, differential diagnosis, or literature search
–Data licensing to pharmaceutical companies raises some conflict-of-interest questions
–Most impactful for solid tumors with actionable molecular targets

Funzionalità chiave

01Comprehensive Genomic Profiling (Tumor & Liquid Biopsy)

02AI-Driven Molecular Analysis

03Clinical Trial Matching Engine (Deep 6 AI)

04Real-World Outcomes Data (30M+ Patient Records)

05Biomarker Identification (PD-L1, MSI-H, TMB, Gene Fusions)

06Treatment Response Prediction

07EHR Integration for Oncology workflows

08Pharmaceutical Research Partnerships

09Transcriptomic and Proteomic Analysis

10Companion Diagnostic Support

Fonti primarie e citazioni

Riferimenti esterni citati in questa recensione. I link si aprono in una nuova scheda.

RegolatorioTempus AI, Inc. — SEC Filing (Form 10-K)U.S. Securities and Exchange Commission BenchmarkOnly 5% of Adult Cancer Patients Enroll in Clinical TrialsNational Cancer Institute

Cosa dicono i medici

Aggiornato a febbraio 2026

“Tempus has become integral to our tumor board discussions. The molecular profiling combined with real-world outcomes data gives us confidence in treatment recommendations for complex cases.”
Medical Oncologist15 ott 2025
Academic Cancer Center

“The trial matching has meaningfully increased our enrollment. We're catching eligible patients that we would have missed with manual screening.”
Clinical Trials Coordinator20 ago 2025
NCI-Designated Cancer Center

“Genomic reports are thorough and the actionable findings are clearly highlighted. Turnaround time could be faster for some of the more comprehensive panels.”
Community Oncologist1 dic 2025
Private Practice

Dettaglio punteggio

Molto buono

Precisione clinica88

Evidenze e citazioni85

Design prodotto82

Integrazione EHR86

Workflow e velocità78

Valore e prezzo55

Perché questa valutazione

Tempus earns a Very Good rating in oncology for its massive genomic dataset and AI-driven clinical trial matching. The platform is the go-to for molecularly guided treatment decisions, though its narrow oncology focus limits general CDS utility.

Basato su 10 recensioni di medici

RankingRecensione per specialità

PrezzoEnterprise / istituzionale

Fondata2015

Visita Tempus

Ideale per

Oncology practices and cancer centers seeking AI-powered precision medicine — da comprehensive genomic profiling to clinical trial matching. The leading platform for connecting a patient's molecular profile to treatment evidence and trial opportunities.

Anche recensiti

Confronto completo